Finnish Red Cross Report issue

Foundation Phase 2 Phase 3

Organization Overview

First Clinical Trial
2004
NCT01119690
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2004

Timeline

NOW
  • Now

Alternative names

Finnish Red Cross | Finnish Red Cross Blood Service

Active Ingredients

Drugs in Phase 3 Trials (1)

allogeneic blood cells (1 trial)

Drugs in Phase 2 Trials (1)

COVID-19 convalescent plasma (1 trial)

Drugs in Other Trials (2)

canola oil (1 trial)

whole blood (1 trial)

Indications

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 4